| Year |
Citation |
Score |
| 2022 |
Currea JP, Frazer R, Wasserman SM, Theobald J. Acuity and summation strategies differ in vinegar and desert fruit flies. Iscience. 25: 103637. PMID 35028530 DOI: 10.1016/j.isci.2021.103637 |
0.666 |
|
| 2021 |
Kanwal JK, Coddington E, Frazer R, Limbania D, Turner G, Davila KJ, Givens MA, Williams V, Datta SR, Wasserman S. Internal state: dynamic, interconnected communication loops distributed across body, brain, and time. Integrative and Comparative Biology. PMID 34115114 DOI: 10.1093/icb/icab101 |
0.679 |
|
| 2018 |
Park EJ, Wasserman SM. Diversity of visuomotor reflexes in two Drosophila species. Current Biology : Cb. 28: R865-R866. PMID 30130502 DOI: 10.1016/J.Cub.2018.06.071 |
0.619 |
|
| 2015 |
Wasserman SM, Frye MA. Group behavior: social context modulates behavioral responses to sensory stimuli. Current Biology : Cb. 25: R467-9. PMID 26035792 DOI: 10.1016/J.Cub.2015.03.052 |
0.523 |
|
| 2015 |
Wasserman SM, Aptekar JW, Lu P, Nguyen J, Wang AL, Keles MF, Grygoruk A, Krantz DE, Larsen C, Frye MA. Olfactory neuromodulation of motion vision circuitry in Drosophila. Current Biology : Cb. 25: 467-72. PMID 25619767 DOI: 10.1016/J.Cub.2014.12.012 |
0.686 |
|
| 2013 |
Wasserman S, Salomon A, Frye MA. Drosophila tracks carbon dioxide in flight. Current Biology : Cb. 23: 301-6. PMID 23352695 DOI: 10.1016/J.Cub.2012.12.038 |
0.556 |
|
| 2012 |
Wasserman S, Lu P, Aptekar JW, Frye MA. Flies dynamically anti-track, rather than ballistically escape, aversive odor during flight. The Journal of Experimental Biology. 215: 2833-40. PMID 22837456 DOI: 10.1242/Jeb.072082 |
0.736 |
|
| 2011 |
Wasserman SM, Beverly M, Bell HW, Sengupta P. Regulation of response properties and operating range of the AFD thermosensory neurons by cGMP signaling. Current Biology : Cb. 21: 353-62. PMID 21315599 DOI: 10.1016/J.Cub.2011.01.053 |
0.691 |
|
| 2010 |
van der Linden AM, Beverly M, Kadener S, Rodriguez J, Wasserman S, Rosbash M, Sengupta P. Genome-wide analysis of light- and temperature-entrained circadian transcripts in Caenorhabditis elegans. Plos Biology. 8: e1000503. PMID 20967231 DOI: 10.1371/Journal.Pbio.1000503 |
0.673 |
|
| 2008 |
Biron D, Wasserman S, Thomas JH, Samuel AD, Sengupta P. An olfactory neuron responds stochastically to temperature and modulates Caenorhabditis elegans thermotactic behavior. Proceedings of the National Academy of Sciences of the United States of America. 105: 11002-7. PMID 18667708 DOI: 10.1073/Pnas.0805004105 |
0.611 |
|
| 2006 |
Biron D, Shibuya M, Gabel C, Wasserman SM, Clark DA, Brown A, Sengupta P, Samuel AD. A diacylglycerol kinase modulates long-term thermotactic behavioral plasticity in C. elegans. Nature Neuroscience. 9: 1499-505. PMID 17086178 DOI: 10.1038/Nn1796 |
0.591 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Limbania D, Turner GL, Wasserman SM. Dehydrated track a water plume in tethered flight. Iscience. 26: 106266. PMID 36915685 DOI: 10.1016/j.isci.2023.106266 |
0.232 |
|
| 2021 |
Hoke KL, Hensley N, Kanwal JK, Wasserman S, Morehouse NI. Spatio-Temporal Dynamics in Animal Communication: A Special Issue Arising from a Unique Workshop-Symposium Model. Integrative and Comparative Biology. PMID 34215880 DOI: 10.1093/icb/icab151 |
0.225 |
|
| 2002 |
Wasserman SM, Mehraban F, Komuves LG, Yang RB, Tomlinson JE, Zhang Y, Spriggs F, Topper JN. Gene expression profile of human endothelial cells exposed to sustained fluid shear stress. Physiological Genomics. 12: 13-23. PMID 12419857 DOI: 10.1152/physiolgenomics.00102.2002 |
0.121 |
|
| 2003 |
Yang RB, Ng CK, Wasserman SM, Kömüves LG, Gerritsen ME, Topper JN. A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. The Journal of Biological Chemistry. 278: 33232-8. PMID 12807873 DOI: 10.1074/jbc.M305022200 |
0.097 |
|
| 2004 |
Wasserman SM, Topper JN. Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications. Vascular Medicine (London, England). 9: 35-45. PMID 15230487 DOI: 10.1191/1358863x04vm521ra |
0.097 |
|
| 1997 |
Topper JN, Wasserman SM, Anderson KR, Cai J, Falb D, Gimbrone MA. Expression of the bumetanide-sensitive Na-K-Cl cotransporter BSC2 is differentially regulated by fluid mechanical and inflammatory cytokine stimuli in vascular endothelium. The Journal of Clinical Investigation. 99: 2941-9. PMID 9185518 DOI: 10.1172/Jci119489 |
0.093 |
|
| 2015 |
Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacology & Therapeutics. 145: 58-66. PMID 25046268 DOI: 10.1016/j.pharmthera.2014.07.004 |
0.091 |
|
| 2002 |
Yang RB, Ng CK, Wasserman SM, Colman SD, Shenoy S, Mehraban F, Komuves LG, Tomlinson JE, Topper JN. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. The Journal of Biological Chemistry. 277: 46364-73. PMID 12270931 DOI: 10.1074/jbc.M207410200 |
0.077 |
|
| 2014 |
Fang F, Wasserman SM, Torres-Vazquez J, Weinstein B, Cao F, Li Z, Wilson KD, Yue W, Wu JC, Xie X, Pei X. The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function. Journal of Cell Science. 127: 1428-40. PMID 24463812 DOI: 10.1242/Jcs.136358 |
0.076 |
|
| 2004 |
Wu BT, Su YH, Tsai MT, Wasserman SM, Topper JN, Yang RB. A novel secreted, cell-surface glycoprotein containing multiple epidermal growth factor-like repeats and one CUB domain is highly expressed in primary osteoblasts and bones. The Journal of Biological Chemistry. 279: 37485-90. PMID 15234972 DOI: 10.1074/jbc.M405912200 |
0.075 |
|
| 2012 |
Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clinical Cardiology. 35: 385-91. PMID 22714699 DOI: 10.1002/clc.22014 |
0.074 |
|
| 2015 |
Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Review of Cardiovascular Therapy. 13: 477-88. PMID 25824308 DOI: 10.1586/14779072.2015.1030395 |
0.066 |
|
| 2014 |
Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clinical Cardiology. 37: 131-9. PMID 24477778 DOI: 10.1002/clc.22248 |
0.062 |
|
| 2014 |
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 129: 234-43. PMID 24255061 DOI: 10.1161/CIRCULATIONAHA.113.007012 |
0.058 |
|
| 2015 |
Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, et al. Cardiovascular drug development: is it dead or just hibernating? Journal of the American College of Cardiology. 65: 1567-82. PMID 25881939 DOI: 10.1016/J.Jacc.2015.03.016 |
0.056 |
|
| 2015 |
Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. The American Journal of Cardiology. PMID 26547291 DOI: 10.1016/j.amjcard.2015.10.021 |
0.055 |
|
| 2014 |
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Jama. 311: 1870-82. PMID 24825642 DOI: 10.1001/Jama.2014.4030 |
0.051 |
|
| 2012 |
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet (London, England). 380: 2007-17. PMID 23141813 DOI: 10.1016/S0140-6736(12)61770-X |
0.05 |
|
| 2016 |
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Češka R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial Jama - Journal of the American Medical Association. 315: 1580-1590. DOI: 10.1001/jama.2016.3608 |
0.05 |
|
| 2014 |
Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clinical Cardiology. 37: 195-203. PMID 24481874 DOI: 10.1002/Clc.22252 |
0.05 |
|
| 2016 |
Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJP, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) American Heart Journal. 176: 83-92. DOI: 10.1016/j.ahj.2016.01.019 |
0.048 |
|
| 2002 |
Wasserman SM, Fann JI, Atwood JE, Burdon TA, Fadel BM. Acquired left ventricular-right atrial communication: Gerbode-type defect. Echocardiography (Mount Kisco, N.Y.). 19: 67-72. PMID 11884258 |
0.046 |
|
| 2012 |
Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 126: 2408-17. PMID 23129602 DOI: 10.1161/CIRCULATIONAHA.112.144055 |
0.044 |
|
| 2015 |
Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. Circulation Research. 117: 731-41. PMID 26228031 DOI: 10.1161/CIRCRESAHA.115.307071 |
0.043 |
|
| 2015 |
Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of evolocumab on Vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized,placebo-controlled DESCARTES study Circulation Research. 117: 731-741. DOI: 10.1161/CIRCRESAHA.115.307071/-/DC1 |
0.041 |
|
| 2023 |
Yano J, Nave C, Larratt K, Honey P, Jingco C, Roberts M, Trotter D, He X, Elezi G, Whitelegge JP, Wasserman S, Donlea JM. Elevated sleep need in a stress-resilient species. Biorxiv : the Preprint Server For Biology. PMID 37292829 DOI: 10.1101/2023.05.27.542279 |
0.041 |
|
| 2016 |
Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy. PMID 26936841 DOI: 10.1007/s10557-016-6655-4 |
0.04 |
|
| 2014 |
Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Journal of the American College of Cardiology. 63: 2541-8. PMID 24694531 DOI: 10.1016/j.jacc.2014.03.019 |
0.039 |
|
| 2013 |
LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. The American Journal of Cardiology. 111: 1221-9. PMID 23375731 DOI: 10.1016/j.amjcard.2012.12.052 |
0.036 |
|
| 2014 |
Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal. 35: 2249-59. PMID 24598985 DOI: 10.1093/eurheartj/ehu085 |
0.035 |
|
| 2012 |
Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet (London, England). 380: 1995-2006. PMID 23141812 DOI: 10.1016/S0140-6736(12)61771-1 |
0.034 |
|
| 2013 |
Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, ... ... Wasserman SM, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 15: 1082-94. PMID 23787718 DOI: 10.1093/eurjhf/hft095 |
0.031 |
|
| 2013 |
Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 128: 2113-20. PMID 24014831 DOI: 10.1161/CIRCULATIONAHA.113.004678 |
0.031 |
|
| 2013 |
Bhandari M, Wasserman SM, Yurgin N, Petrisor B, Sprague S, Dent RE. Development and preliminary validation of a Function IndeX for Trauma (FIX-IT). Canadian Journal of Surgery. Journal Canadien De Chirurgie. 56: E114-20. PMID 24067526 DOI: 10.1503/cjs.004312 |
0.031 |
|
| 2014 |
Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Journal of the American College of Cardiology. 63: 430-3. PMID 24161333 DOI: 10.1016/j.jacc.2013.09.048 |
0.028 |
|
| 2015 |
Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. Jacc. Heart Failure. 3: 22-9. PMID 25453536 DOI: 10.1016/j.jchf.2014.07.009 |
0.028 |
|
| 2010 |
Abraham WT, Anand IS, Klapholz M, Ponikowski P, Scarlata D, Wasserman SM, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in heart failure. Congestive Heart Failure (Greenwich, Conn.). 16: 87-95. PMID 20557327 DOI: 10.1111/j.1751-7133.2010.00142.x |
0.028 |
|
| 2014 |
Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, et al. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research. 55: 2370-9. PMID 25258384 DOI: 10.1194/jlr.M053207 |
0.028 |
|
| 2014 |
Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circulation Journal : Official Journal of the Japanese Circulation Society. 78: 1073-82. PMID 24662398 DOI: DN/JST.JSTAGE/circj/CJ-14-0130 |
0.027 |
|
| 2015 |
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine. 372: 1500-9. PMID 25773607 DOI: 10.1056/NEJMoa1500858 |
0.027 |
|
| 2013 |
Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 127: 2222-30. PMID 23733968 DOI: 10.1161/CIRCULATIONAHA.113.002033 |
0.027 |
|
| 2015 |
Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia Expert Review of Cardiovascular Therapy. 13: 477-488. DOI: 10.1586/14779072.2015.1030395 |
0.026 |
|
| 1990 |
Williams SA, Boolell M, MacGregor GA, Smaje LH, Wasserman SM, Tooke JE. Capillary hypertension and abnormal pressure dynamics in patients with essential hypertension. Clinical Science (London, England : 1979). 79: 5-8. PMID 2167790 |
0.025 |
|
| 1979 |
Wasserman SM, Cohen JA. Spontaneous migration of an intracranial bullet fragment. The Mount Sinai Journal of Medicine, New York. 46: 512-5. PMID 395441 |
0.024 |
|
| 2009 |
Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM, van Veldhuisen DJ. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure. 11: 1071-7. PMID 19815661 DOI: 10.1093/eurjhf/hfp130 |
0.024 |
|
| 2008 |
Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 117: 526-35. PMID 18195176 DOI: 10.1161/Circulationaha.107.698514 |
0.023 |
|
| 2013 |
Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 128: 962-9. PMID 23884353 DOI: 10.1161/CIRCULATIONAHA.113.001969 |
0.023 |
|
| 2011 |
Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet (London, England). 378: 676-83. PMID 21856481 DOI: 10.1016/S0140-6736(11)61126-4 |
0.022 |
|
| 2012 |
Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. Journal of the American College of Cardiology. 60: 1888-98. PMID 23083772 DOI: 10.1016/J.Jacc.2012.08.986 |
0.022 |
|
| 2016 |
Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: A meta-analysis of individual patient data The Lancet Diabetes and Endocrinology. DOI: 10.1016/S2213-8587(16)00003-6 |
0.022 |
|
| 2012 |
Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Jama. 308: 2497-506. PMID 23128163 DOI: 10.1001/jama.2012.25790 |
0.017 |
|
| 2008 |
Nguyen PK, Wasserman SM, Fann JI, Giacomini J. Successful lysis of an aortic prosthetic valve thrombosis with a dosing regimen for peripheral artery and bypass graft occlusions. The Journal of Thoracic and Cardiovascular Surgery. 135: 691-3. PMID 18329497 DOI: 10.1016/j.jtcvs.2007.11.012 |
0.015 |
|
| 2014 |
Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. Journal of the American College of Cardiology. 63: 1278-88. PMID 24509273 DOI: 10.1016/j.jacc.2014.01.006 |
0.015 |
|
| 2014 |
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. The New England Journal of Medicine. 370: 1809-19. PMID 24678979 DOI: 10.1056/NEJMoa1316222 |
0.015 |
|
| 2015 |
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, ... ... Wasserman SM, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 385: 331-40. PMID 25282519 DOI: 10.1016/S0140-6736(14)61399-4 |
0.015 |
|
| 2008 |
Patel H, Ekman I, Spertus JA, Wasserman SM, Persson LO. Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire in a Chronic Heart Failure population. European Journal of Cardiovascular Nursing : Journal of the Working Group On Cardiovascular Nursing of the European Society of Cardiology. 7: 214-21. PMID 18060843 DOI: 10.1016/j.ejcnurse.2007.08.005 |
0.013 |
|
| 2014 |
Wasserman S, Clowse MEB. Systemic lupus erthematosus Contraception and Pregnancy in Patients With Rheumatic Disease. 79-97. DOI: 10.1007/978-1-4939-0673-4_4 |
0.013 |
|
| 2015 |
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 385: 341-50. PMID 25282520 DOI: 10.1016/S0140-6736(14)61374-X |
0.011 |
|
| 2008 |
Van Veldhuisen DJ, Wasserman SM, Baker N. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regiments of darbepoetin alfa in patients with heart failure and anaemia: Reply European Heart Journal. 29: 566-567. DOI: 10.1093/eurheartj/ehm600 |
0.011 |
|
| 2016 |
Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM, et al. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology. 67: 1444-55. PMID 27012405 DOI: 10.1016/j.jacc.2016.01.031 |
0.01 |
|
| 2016 |
Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal. 173: 94-101. PMID 26920601 DOI: 10.1016/j.ahj.2015.11.015 |
0.01 |
|
| 2016 |
Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GBJ, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial Clinical Cardiology. DOI: 10.1002/clc.22518 |
0.01 |
|
| 2015 |
Sabatine MS, Wasserman SM, Stein EA. PCSK9 Inhibitors and Cardiovascular Events. The New England Journal of Medicine. 373: 774-5. PMID 26295078 |
0.01 |
|
| 2014 |
Blom DJ, Wasserman SM, Stein EA. Evolocumab in hyperlipidemia. The New England Journal of Medicine. 371: 877-8. PMID 25162896 DOI: 10.1056/NEJMc1408237 |
0.01 |
|
| 2014 |
Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. Journal of the American College of Cardiology. 63: 2531-40. PMID 24691094 DOI: 10.1016/j.jacc.2014.03.018 |
0.01 |
|
| 2014 |
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine. 370: 412-20. PMID 24382002 DOI: 10.1056/NEJMoa1305224 |
0.01 |
|
| 2013 |
Stein EA, Wasserman SM, Dias C, Scott R, Raal F. Anti-PCSK9 monoclonal antibody treatment of lipoprotein disorders Drugs of the Future. 38: 451-459. DOI: 10.1358/dof.2013.038.07.1981967 |
0.01 |
|
| 2009 |
McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure. 11: 795-801. PMID 19633103 DOI: 10.1093/eurjhf/hfp098 |
0.01 |
|
| 2007 |
van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal. 28: 2208-16. PMID 17681958 DOI: 10.1093/eurheartj/ehm328 |
0.01 |
|
| 2007 |
Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology. 49: 753-62. PMID 17306703 DOI: 10.1016/j.jacc.2006.11.024 |
0.01 |
|
| 2006 |
Wasserman SM, Topper JN. The endothelium Vascular Medicine. 1-15. DOI: 10.1016/B978-0-7216-0284-4.50007-5 |
0.01 |
|
| Hide low-probability matches. |